文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

阿米卡星治疗耐多药结核病的剂量系统综述

Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.
PubMed 文献 · Clin Infect Dis · 2018-01-01

该系统综述检索阿米卡星治疗耐多药结核病的药代动力学与药效学文献,仅纳入5篇相关研究。综述认为Cmax/MIC是最重要的疗效PK/PD指标,感染部位目标Cmax/MIC应为10,累积AUC与治疗天数增加毒性风险。

要点

  • 阿米卡星疗效关键PK/PD指标为Cmax/MIC,感染部位目标比值为10。
  • 累积AUC与累积治疗天数增加与毒性风险升高相关。
  • 阿米卡星用于MDR-TB逾40年但PK数据极少,需更多研究。

核心结论

  • 阿米卡星与MIC相关的最高浓度(Cmax)是疗效的最重要PK/PD指标。
  • 感染部位目标Cmax/MIC比值应为10。
  • 累积浓度-时间曲线下面积(AUC)与累积治疗天数相关,并增加毒性风险。

研究设计与样本

  • 系统综述,检索阿米卡星作为耐多药结核病二线药物的药代动力学与药效学文献。
  • 共纳入5篇包含阿米卡星PK、结核空心纤维系统模型或早期杀菌活性数据的文章。

主要发现

  • 尽管阿米卡星用于MDR-TB治疗已超过40年,可用的PK数据非常少。
  • Cmax与MIC相关的PK/PD指标被确定为疗效的最重要指标。
  • 累积AUC对应累积治疗天数与毒性风险增加相关。

关键数值与推荐

  • 感染部位目标Cmax/MIC比值应为10。

临床怎么用

  • MDR-TB方案中使用阿米卡星时应关注Cmax/MIC比值以优化疗效。
  • 需监测累积AUC与治疗天数以评估毒性风险。

局限性

  • 符合纳入标准的文献仅5篇,阿米卡星PK数据非常有限。
  • 综述强调需要更多研究以确定最佳剂量和给药频率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Amikacin has been used for over 40 years in multidrug resistant tuberculosis (MDR-TB), but there is still debate on the right dose. The aim of this review was to search relevant pharmacokinetic (PK) and pharmacodynamic (PD) literature for the optimal dose and dosing frequency of amikacin in MDR-TB regimens trying to optimize efficacy while minimizing toxicity. METHODS: A systematic review on the value of amikacin as second-line drug in the treatment of MDR-TB was performed. RESULTS: Five articles were identified with data on PK, hollow-fiber system model for TB and or early bactericidal activity of amikacin. Despite the long period in which amikacin has been available for the treatment of MDR-TB, very little PK data is available. This highlights the need for more research. CONCLUSIONS: Maximum concentration (Cmax) of amikacin related to MIC proved to be the most important PK/PD index for efficacy. The target Cmax/MIC ratio should be 10 at site of infection. Cumulative area under the concentration-time curve (AUC) corresponding with cumulative days of treatment was associated with an increased risk of toxicity.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sturkenboom MGG, Simbar N, Akkerman OW, et al. Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. Clin Infect Dis. 2018. PMID: 30496466. doi:10.1093/cid/ciy613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。